A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study

Plerixafor and autologous stem cell transplantation

“…This effect explains the lack of patient response to G-CSF stimulation and this is in agreement with the results of previous studies [22,23].…”

Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte–colony‐stimulating factor [G‐CSF], G‐CSF plus plerixafor, or cyclophosphamide G‐CSF/granulocyte‐macrophage [GM]‐CSF) on number of colony‐forming unit–GM, engraftment, and Day +100 hematopoietic graft function

“…In fact, Donahue and colleagues 20 found a distinct pattern of gene expression on G+P‐mobilized CD34+ cells with relative up regulation of genes and miRNAs implicated in T‐cell and B‐cell differentiation and down regulation of the ones expressed in granulocyte precursors. It has also been hypothesized that G+P products have a relative increase in the more primitive CD34+/CD38− subpopulation of CD34+ cells 21 . Combined, these findings may partially explain a slightly decreased number of GM‐CFU and delayed neutrophil engraftment but similar long‐term hematopoietic graft function obtained with G+P products.…”

A New Source of Mesenchymal Stem Cells for Articular Cartilage Repair

“…24 The addition of AMD3100 to G-CSF resulted in significant increases in circulating CD34(1) cells compared with G-CSF only, which led to a synergistic effect. 18 This combination therapy has recently shown greater efficacy compared with G-CSF only in phase 3 clinical trials. 8 Moreover, G-CSF is commonly used to mobilize HSCs into peripheral circulation.…”